Company intelligence / Profile preview
Setara Biosciences
- Ownership
- Private
- Development stage
- Other
Overview
Setara Biosciences is a private, clinical-stage biotechnology company developing genetics-driven precision medicines for severe rare diseases and related larger-population indications. The company was formed in 2026 to advance the non-ABS-1230 pipeline remaining after Jazz Pharmaceuticals acquired Actio Biosciences. Its lead program, STAR-0871, is an oral small-molecule inhibitor of TRPV4 being developed for Charcot-Marie-Tooth disease type 2C and overactive bladder. Setara also has undisclosed discovery-stage programs addressing genetic epilepsies, migraine, and other rare genetic diseases. The company launched with a $90 million Series A financing and is led by Actio Biosciences co-founders David Goldstein and David Breckenridge.
- Therapeutic areas
- UrologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Setara Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Setara Biosciences.